Exenatide Is Neuroprotective in a New Rabbit Model of Hypoxia-Ischemia

Area of Science:

• Neuroscience
• Neonatal Research
• Pharmacology

Background:

• Perinatal hypoxia-ischemia (HI) is a global neonatal complication.
• Animal models are crucial for understanding HI pathophysiology and testing therapies.
• Exenatide, a type 2 diabetes drug, shows neuroprotective effects in rodent HI models.

Purpose of the Study:

• To establish a reproducible hypoxia-ischemia model in rabbit kits at postnatal day 3-4.
• To evaluate the neuroprotective efficacy of exenatide in this new rabbit model.
• To assess the safety and tolerability of exenatide in neonatal rabbits.

Main Methods:

• Developed a hypoxia-ischemia model in rabbit kits at postnatal day 3-4.
• Administered varying doses of exenatide (170 μg/g, 500 μg/g) or vehicle post-hypoxia-ischemia.
• Conducted histological assessments of brain tissue loss seven days post-insult.
• Monitored glucose, ketone bodies, body weight, and temperature in a separate cohort.

Main Results:

• A 500 μg/g dose of exenatide, given once or twice, reduced brain tissue loss by 90% in rabbit kits at P3 and P4.
• Exenatide caused a transient, 2-fold increase in ketone bodies within 6 hours.
• No significant effects on glucose levels, body temperature, or weight gain were observed.
• Exenatide demonstrated safety and good tolerability in the rabbit hypoxia-ischemia model.

Conclusions:

• Exenatide is a potent neuroprotective agent in a novel rabbit model of perinatal hypoxia-ischemia.
• The rabbit model at P3-4 offers a valuable platform for studying neonatal brain injury and therapeutic interventions.
• Exenatide's safety profile and efficacy suggest its potential as a therapeutic option for neonatal hypoxic-ischemic encephalopathy.